Skip to content

Dose Response Bioavailability of Coffee and Green Tea Antioxidants in Humans

Dose Response Bioavailability of Coffee and Green Tea Antioxidants in Humans

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01089920
Enrollment
23
Registered
2010-03-19
Start date
2009-09-30
Completion date
2010-02-28
Last updated
2014-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Brief summary

Coffee and green tea are 2 widely consumed beverages. Both contain polyphenol antioxidant compounds (chlorogenic acids for coffee and catechins for tea). The bioavailability of catechins is somewhat known and has been referenced in the literature. However, bioavailability data from tea infusion is non-existent, even though it reflects better how consumers drink this beverage. In addition, bioavailability of coffee chlorogenic acids is less understood and no dose response study has been reported so far in the literature. Thus, there is a great need to understand and reinforce our knowledge on the bioavailability of coffee and tea polyphenol compounds.

Interventions

OTHERGreen tea

Infusion (tea bags) from commercially available green tea

OTHERCoffee

Soluble coffee commercially available

Sponsors

Société des Produits Nestlé (SPN)
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* 18 - 65 years, male and female * Healthy as determined by the medical questionnaire and the medical visit * Normal weight: BMI 18 - 25 * Coffee drinkers with an average consumption of 2-5 cups per day * Having given informed consent

Exclusion criteria

* Intestinal or metabolic diseases / disorders such as diabetic, renal, hepatic, hypertension, pancreatic or ulcer * Have had a gastrointestinal surgery, except appendicectomy * Difficulty to swallow * Have a regular consumption of medication * Have taken antibiotic therapy within the last 6 months * Alcohol consumption \> 2 units a day * Smokers (more than 5 cigarettes per day) * Have given blood within the last 3 weeks * Volunteers who cannot be expected to comply with treatment * Currently participating or having participated in another clinical trial during the last 3 weeks

Design outcomes

Primary

MeasureTime frame
Compare plasma Area under the curve (AUC) of highest and lowest dose of coffee for chlorogenic and phenolic acid metabolitesMeasurements done over 24h after ingestion

Secondary

MeasureTime frame
Compare Area under the curve (AUC), Maximum plasma concentration (Cmax), Time to reach maximum plasma concentration (Tmax) and half-life (T1/2) of all three doses of coffee for chlorogenic and phenolic acid metabolitesMeasurements done over 12h after ingestion
Compare AUC, Cmax, Tmax and T1/2 of all three doses of green tea for catechin metabolitesMeasurements done over 12h after ingestion

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026